LIPOPOLYSACCHARIDE RECOGNITION AND SIGNALING
Lipopolysaccharide (LPS, endotoxin) is a glycolipid that is embedded in the outer membrane of gram-negative bacteria and plays a crucial role in maintaining the structural integrity of the organism (1, 2). Lipopolysaccharide is composed of three major biochemical domains (Fig. 1). The O-specific chain is a repetitive glycan polymer that projects outside the outer membrane onto the surface of bacteria. The presence and structure of the O-specific chain contribute to the antigenicity, morphological appearance, and antibiotic sensitivity of gram-negative bacteria (3). The core domain is a phosphorylated oligosaccharide that links the O-specific chain to the lipid A moiety and is important for maintaining structural viability (4). Lipid A is a heat-stable phosphorylated glucosamine disaccharide with multiple fatty acid side chains that anchors the LPS molecule into the lipid bilayer of the bacterial outer membrane (5). Release of lipid A into the local environment requires disruption of the microbial outer membrane, which occurs as a result of microbial proliferation and death.
Lipid A is avidly recognized by leukocytes and other cell types and is the major factor that alerts the immune system to the presence of infection with gram-negative organisms. The importance of lipid A recognition is evident by the widespread expression of the endotoxin receptor complex on macrophages, neutrophils, dendritic cells, mast cells, endothelial cells, and natural killer cells as well as several populations of parenchymal cells (6, 7). Cells recognize lipid A via a surface receptor complex that is composed of the proteins myeloid differentiation factor 2 (MD2) and Toll-like receptor 4 (TLR4) (8, 9) (Fig. 2). Lipopolysaccharide-binding protein, as well as the membrane-bound and soluble forms of CD14, binds LPS in the systemic and interstitial environments and plays important roles in facilitating the presentation of LPS to the endotoxin receptor complex (10). Binding of LPS to MD2 causes conformational changes in TLR4 that facilitate TLR4 dimerization or oligomerization and activation of downstream signaling (9, 11). Toll-like receptor 4 activation triggers two major downstream intracellular signaling pathways, one that depends on the adaptor protein myeloid differentiation factor 88 (MyD88) and the other that requires recruitment of Toll–interleukin 1 (IL-1) receptor (TIR) domain–containing adaptor-inducing interferon β (TRIF) (12) (Fig. 2). Activation of the MyD88-dependent signaling pathway is precipitated by conformational changes in the intracellular TIR domain of TLR4, which facilitates recruitment of the linking proteins TIRAP and MyD88 (13, 14). The clustering of IL receptor–associated kinase 4 (IRAK4) molecules on MyD88 facilitates IRAK1 phosphorylation and activation, recruitment of TRAF6, and engagement of TAK1 (15). TAK1 activates mitogen-activated protein kinases (MAPKs) and the transcription factor activator protein 1 (AP-1) as well as IκB kinases that facilitate activation of the nuclear factor κB (NF-κB) pathway. Activator protein 1 and NF-κB translocate to the nucleus to facilitate transcription of proinflammatory gene products such as tumor necrosis factor α (TNF-α), IL-12, and inducible nitric oxide synthase, among others (16).
After activation of the MyD88-associated pathway, the LPS/MD-2/TLR4 conglomerate translocates to endosomes and associates with the linking proteins TRIF and TRAF3 (Fig. 2). Endosomal compartmentalization is made possible through activation of phosphatidylinositol-3-OH kinase (PI3K), specifically the p110δ isoform, which leads to the generation of phosphatidylinositol-[3,4,5]-triphosphate (IPI3). The result is dissociation of MAL (MyD88-adapter-like) from the plasma membrane leading to its degradation (17). Toll–IL-1 receptor domain–containing adaptor-inducing interferon β facilitates delayed activation of the MAPK/AP-1 and NF-κB signaling pathways through engagement of TRAF-6 and RIP-1, respectively (18). The TBK/interferon regulatory factor 3 pathway is activated by TRAF3 and results in the production of type I interferons (IFNs) and their associated gene products (19). The endotoxin receptor complex is ultimately sorted to late endosomes/lysosomes for degradation and signal termination (20). Toll-like receptor 4 is unique among Toll-like receptors in that its activation induces both MyD88- and TRIF-dependent signaling (21). All other TLRs selectively signal through either the MyD88- or TRIF-dependent signaling pathways.
THE FAMILY OF TLR4 AGONISTS
Lipid A is the bioactive component of the LPS molecule. Native Escherichia coli lipid A is composed of a disaccharide backbone containing two phosphate groups and six acyl side chains (Fig. 3) (22). That structural conformation, which is common to many gram-negative bacteria, strongly activates TLR4 signaling and has potent proinflammatory activity (23). Yet, alterations in lipid A structure can markedly affect host responses. Differences in the number, arrangement, and length of acyl side chains as well as the location and conformation of charged groups greatly alter the biological properties of lipid A mimetics. Hexa-acylated, diphosphoryl lipid A, as described above for native lipid A from E. coli, potently induces proinflammatory cytokine production. However, tetra-acylated lipid A is a TLR4 antagonist (4). Other manipulations of the lipid A structure result in molecules that preferentially activate MyD88- or TRIF-dependent signaling, respectively. Large-scale MyD88 activation causes production of proinflammatory mediators, which are important for local clearance of bacteria but can be harmful when overproduced systemically (24). Thus, the inflammatory adverse effects of most MyD88-biased immunomodulators preclude their use in the clinical setting (25, 26). Activation of the TRIF-dependent signaling pathway induces production of type I IFNs (IFN-α/β),which are important for generating an effective host response to viral and bacterial infection and facilitating the immunoadjuvant activity of lipid A mimetics (27) (Fig. 2). Recent studies indicate that TRIF-biased TLR4 agonists are attractive immunomodulators because of their potency as immunoadjuvants and low inflammatory toxicity (28, 29).
Investigators in academia and industry are working to produce lipid A mimetics that have desirable biological properties using both de novo synthesis and bacterial engineering. The de novo synthesis of homogeneous lipid A mimetics has been complicated by difficulties in producing compounds that possess consistent acyl chain length and conformation. Bioengineering approaches have encountered similar difficulties. Bacteria have been generated that can produce monophophorylated lipid A, but challenges have arisen in generating moieties with optimized acyl chain numbers and conformation. Numerous efforts have been made to engineer E. coli and Salmonella species to produce single lipid A species. Those attempts have been complicated by numerous factors, the most important being the requirement of LPS heterogeneity to optimize the stability of the bacterial outer membrane. However, recent studies have reported the use of combinatorial enzyme expression strategies that appear effective in engineering E. coli to produce selective and structurally homogeneous lipid A subtypes and possess potent immunoadjuvant activity (22).
Monophosphoryl lipid A (MPLA) is a heterogeneous mixture of lipid A derivatives created by successive acid and base hydrolysis of lipid A from Salmonella minnesota 595 (30). The predominant species created from that process is 3-O-deacyl-4-MPLA (Fig. 3). Monophosphoryl lipid A possesses attractive biological characteristics as an immunoadjuvant such as augmentation of T helper 1 (TH1) activity and antigen-induced T-cell clonal expansion. Systemic administration of MPLA will induce endotoxin tolerance in humans and experimental animals as indicated by a reduction of circulating proinflammatory cytokine concentrations and attenuation of hemodynamic alterations in response to a subsequent LPS challenge (31, 32). Yet, MPLA possesses approximately 1/1,000th of the systemic proinflammatory activity of native E. coli lipid A in humans (4). That characteristic is likely due to weak MPLA-induced activation of the MyD88-dependent signaling pathway. Compared with native lipid A, MPLA inefficiently induces recruitment of TRAF6 to IRAK-1, resulting in attenuated activation of MAPK and NF-κB signaling, an effect that appears to be secondary to inefficient MPLA-induced TLR4/MD-2 heterodimerization (33). However, MPLA potently activates TRIF-dependent signaling as indicated by phosphorylation of interferon regulatory factor 3 and induction of TRIF-biased gene products such as CXCL10, MCP-1, and RANTES (22, 28). Because of the described biological properties, alum-absorbed MPLA has gained worldwide acceptance as an adjuvant in vaccine preparations and is a component of commercially available papillomavirus and hepatitis virus vaccines (34). Thus, MPLA currently serves as the standard for TLR4-based immunoadjuvants.
Other attractive lipid A mimetics are also under development. Of note, Bowen et al. (35) described a series of monosaccharide lipid A mimetics termed aminoalkyl glucosaminide-4-phosphates (AGPs) and reported the biological properties of two AGPs known as CRX-527 and CRX-547 (Fig. 3). The compounds contain three (R)-3-decanoyloxytetradecanoyl residues that are N- or O-linked to an O-glucosaminyl serine backbone. They differ only in the configuration of the seryl stereocenter. CRX-527 potently induces production of both MyD88 (e.g., TNF-α)- and TRIF (e.g., CXCL10, RANTES)-dependent cytokines by cultured human monocytes and dendritic cells, whereas CRX-547 retains the ability to induce TRIF-dependent cytokines while production of MyD88-dependent gene products is attenuated. CRX-547–induced RANTES production requires TLR4 endocytosis and activation of TRIF-dependent signaling. Nuclear factor κB pathway activation and translocation are minimal. Thus, CRX-547 has characteristics that are biologically similar to MPLA. The efficacy of CRX-547 as an immunomodulator in vivo remains to be further investigated.
THE PHENOMENON OF ENDOTOXIN TOLERANCE
Exposure to low or moderate doses of LPS or lipid A results in a state of “endotoxin tolerance” that renders the host hyporesponsive to a subsequent LPS or lipid A challenge. Endotoxin tolerance is characterized by attenuated production of proinflammatory cytokines such as TNF-α, IL-6, and IFN-γ and increased production of anti-inflammatory mediators such as IL-10, transforming growth factor β, and IL-1 receptor antagonist in response to a second endotoxin challenge (36–38). Those alterations allow the endotoxin-tolerant host to survive a normally lethal secondary challenge with endotoxin. Thus, endotoxin tolerance is thought to be an adaptive mechanism designed to protect the host from inflammatory injury caused by repeated or excessive exposure to LPS or gram-negative infection (39). Moreover, the phenomenon is not limited to protection from high-dose LPS challenge. Lipopolysaccharide priming also attenuates proinflammatory cytokine production in response to other inflammatory stimuli such as gram-positive infection, ischemia-reperfusion injury, or hemorrhagic shock (39–41). The primary cells involved in endotoxin tolerance are monocytes, dendritic cells, and macrophages, essentially all cells that express CD14 (42, 43). On initial exposure to LPS, an increased production of IL-1, TNF-α, IL-6, and IL-8 is observed. However, in cells that are CD14+, re-exposure to LPS results in reduced cytokine production (43).
Cross tolerance has also been shown to exist between TLR agonists. Lipopolysaccharide exposure attenuates proinflammatory cytokine production in response to agonists for other Toll-like receptors (TLR2, TLR5, etc), whereas non-TLR4 agonists induce cross tolerance to LPS challenge (44–46). Some concerns exist that perceived cross tolerance among TLR agonists may have been caused by contamination of supposedly pure TLR agonist preparations with agonists for other TLR (47). For example, some studies were performed using LPS preparations that may have been contaminated with agonists for TLR2. However, follow-up studies using ultrapure TLR agonist preparations have supported the concept of cross-tolerance between TLR agonists (48). Thus, the phenomenon of LPS tolerance appears to be a broadly applied mechanism to regulate acute proinflammatory responses and protect the host from inflammation-induced injury.
A variety of molecular mechanisms have been described that underlie the development of endotoxin tolerance, which might best be characterized as a state of “cellular reprogramming” (41). Defects in TLR4 signaling have been described at the receptor, adaptor protein, signaling molecule, and transcription factor levels and likely represent negative feedback at multiple levels (39) (Table 1). At present, most alterations in TLR4 signaling have mapped to the MyD88-dependent pathway. However, some studies have implicated a role for the TRIF pathway in the development of LPS tolerance, but further research is needed to define specific mechanisms (19, 49).
Initial LPS exposure induces robust TLR4-mediated activation of NF-κB and AP-1 (Fig. 2). As noted earlier in this review, NF-κB and AP-1 translocations are the major factors that regulate the expression of proinflammatory gene products in response to LPS (50). At the same time, inhibitors of TLR4, NF-κB, and AP-1 signaling are induced such as inhibitor of κB (IκB), MAPK phosphatase 1, IRAK-M, suppressor of cytokine signaling 1 (SOCS-1), and RelB (36, 51, 52). Those inhibitors attenuate NF-κB and AP-1 activation and translocation and serve to regulate the LPS-induced inflammatory response to prevent uncontrolled expression of proinflammatory mediators. IκBα sequesters p65/RelA heterodimers in the cytoplasm, reduces nuclear translocation, and decreases production of LPS-induced gene products (53). The function of IRAK-1, which is essential for mobilization of p65 from the cytoplasm, is disrupted by IRAK-M (54). RelB forms heterodimers with p50 and generates a transcriptional suppressor that decreases LPS-induced proinflammatory gene expression (55). Additional studies show that RelB silences gene transcription by binding to histone methyltransferase G9A (56). Similarly, overexpression of NF-κB p50 homodimers has been described during endotoxin tolerance. The transcriptionally inactive p50 homodimers compete for binding with activating p50/p65 on NF-κB consensus sequences on gene promoters and act to inhibit proinflammatory gene expression (57). Mitogen-activated protein kinase phosphatase 1 serves to reduce MAPK phosphorylation and, ultimately, attenuates AP-1 translocation (58). Evidence indicates that LPS-induced expressions of MAPK phosphatase 1, RelB, and IRAK-M are induced by activation of the PI3K pathway. Thus, PI3K activation may facilitate the development of LPS tolerance (59).
At the nuclear level, changes in histone methylation, acetylation, and ubiquitination have been described that cause changes in gene transcription. Foster and colleagues (60) described selective chromatin modifications after LPS exposure that resulted in suppressed expression of many proinflammatory gene products but sustained or increased suppression of other gene products that are typically important for antimicrobial immunity. Other recent work has implicated inhibitory microRNA (miRNA) expression as a mechanism of posttranscriptional downregulation of proinflammatory gene expression after LPS exposure. Lipopolysaccharide treatment augments the expression of miRNAs such as miR146 and miR155 (61). The miR146 attenuates proinflammatory gene expression by antagonizing IL-1R and TLR4 signaling through posttranscriptional regulation of IRAK-1 and TRAF-6 (62). IκB kinase ε is targeted by miR155, resulting in alterations in TLR4/NF-κB signaling (63). Altered expression of other miRNAs has also been described in models of endotoxin tolerance. Further work is needed to fully define their molecular mechanisms of action. Histone methylation is another documented mechanism of proinflammatory gene silencing during endotoxin tolerance. Studies show that chromatin binding of HMGB1 and histone H1, which is facilitated by G9A-facilitated histone H3K9 methylation, is responsible for TNFα gene silencing in endotoxin tolerant human leukemic monocytes (THP-1 cells) (64, 65).
Suppression of cytokine signaling has also been observed during endotoxin tolerance. Suppressor of cytokine signaling 1 is a potent inhibitor of JAK-STAT signaling. Nakagawa et al. (66) reported that SOCS-1 is rapidly induced by LPS and that SOCS-1–deficient mice are highly sensitive to LPS-induced inflammatory injury. The group further reported that SOCS-1–deficient mice do not develop endotoxin tolerance. In a separate study, Liu and colleagues (67) reported that SOCS-1 facilitated the endotoxin-tolerant phenotype by inhibiting NF-κB signaling.
In contrast to LPS tolerance, more recent work has shown that exposure to ultralow doses of LPS (<100 pg/mL) will actually prime the host to mount an exaggerated inflammatory response. Work by Deng et al. (59) shows that exposure to very-low-dose LPS removes transcriptional suppressors from the promoters of proinflammatory genes and sensitizes the host to inflammatory challenge. In that setting, the production of proinflammatory mediators is amplified in response to a secondary inflammatory stimulus, resulting in amplification of inflammatory injury. Evidence indicates that low-dose LPS exposure suppresses PI3K signaling and, consequently, RelB expression. The decrease in RelB primes the host for an amplified proinflammatory response upon secondary LPS exposure. This is in contrast to RelB induction that occurs in response to treatment with LPS at doses of greater than 1 ng/mL. Based on their findings, Deng et al. (59) postulate that PI3K/RelB signaling serves as a switch to differentiate between LPS priming and tolerance. They further hypothesize that chronic exposure to low concentrations of LPS may predispose patients with obesity, aging, or low-grade infection to morbidity and mortality in response to a normally innocuous inflammatory insult.
Many investigators have postulated that endotoxin tolerance renders the host more susceptible to secondary infections and represents a state of immunosuppression. This presumption is based on the attenuated proinflammatory cytokine response present in the endotoxin-tolerant host, which has also been observed in patients with sepsis, major trauma, and thermal injury, all of which are predisposed to secondary infections (41, 68, 69). Monocytes and macrophages harvested from immunocompromised patients with sepsis exhibit suppressed LPS-induced cytokine production, a characteristic that resembles the endotoxin-tolerant phenotype (39). However, recent evidence indicates that prior exposure to lipid A mimetics may actually augment the host response to infection. Thus, despite affecting cytokine responses in similar ways, the functional response to secondary infection may be quite different when comparing the LPS-tolerant host to those with trauma, burns, and sepsis.
BIOLOGICAL PROPERTIES OF TLR4-BASED IMMUNOADJUVANTS
Because of their ability to stimulate innate and adaptive immune responses, TLR4 agonists have emerged as attractive vaccine adjuvants. The high-fidelity antibody responses that are induced by modern vaccines require T helper cells to facilitate isotype switching, B-cell maturation, and more robust immunoglobulin production (Fig. 4). Toll-like receptor 4 agonists induce T-cell activation, clonal expansion, and TH1 polarization indirectly through stimulation and recruitment of antigen-presenting cells (APCs) such as dendritic cells, macrophages, and monocytes (28, 70). Kwissa and colleagues (70) showed that intradermal injection of MPLA into nonhuman primates induces recruitment of CD14+CD16− monocytes and myeloid dendritic cells into draining lymph nodes. Native lipid A also potently induces chemoattraction of APCs at sites of injection (71). The recruited APCs exhibit an activated phenotype characterized by increased class II major histocompatibility complex and costimulatory (e.g., CD80/86/40) molecule expression, more robust antigen presentation, and enhanced cytokine and chemokine production (72, 73).
Unlike alum, which tends to generate TH2 responses, TLR4 agonists facilitate TH1 polarization characterized by robust production of IFN-γ and isotype switching to opsonizing IgG1 and IgG3 immunoglobulins (74–76). Monophosphoryl lipid A, as well as other TLR4 agonists, also potently induces antigen-specific T-cell clonal expansion and primes the expanded T-cell populations for long-term survival (28, 77). Although B cells are reported to express TLR4 and play an active role in eliciting T cell help during humoral immune responses, little is known about the direct impact of TLR4 agonists on the antigen-presenting and T-cell activation properties of B cells. Based on current understanding, it appears that the expansion of antigen-specific TH1 cells by APC facilitates B cell–mediated T cell help, which augments B-cell activation, isotype switching, and immunoglobulin production (Fig. 4).
Monophosphoryl lipid A is currently the only TLR4 agonist used in commercially available vaccine preparations and is a component of available human papillomavirus (HPV) and hepatitis B vaccine preparations (28). Adding MPLA to vaccine preparations boosts serum antibody titers by 10- to 20-fold compared with vaccine alone and preferentially induces production of IgG2a (78). Current vaccines utilize MPLA absorbed onto aluminum hydroxide or aluminum phosphate, a preparation known as ASO4. Addition of ASO4 to existing hepatitis B vaccine induced higher antibody titers and increased rates of seroprotection in immunocompromised patients (79). ASO4 was also effective in boosting antibody titers when added HPV-16 and HPV-18 vaccines (80). In all cases, MPLA-containing vaccine preparations were well tolerated and generated adverse effect profiles that were similar to existing vaccines (81). A small increase in the incidence of pain, erythema, and swelling at the injection site was noted in ASO4-containing vaccine preparations, but compliance with the vaccine schedule was maintained, and the incidence of serious events was not increased (82, 83). That safety profile was sufficient to allow for licensure of ASO4-containing vaccines in Europe, the United States, and Argentina. Because of the success of MPLA as a vaccine adjuvant, numerous laboratories have produced and evaluated new lipid A mimetics as potential vaccine adjuvants and immunomodulators (35, 75, 84). However, none of the other preparations are available in commercially produced vaccine preparations.
Recent studies show that the immunoadjuvant effects of TLR4 agonists are biased toward activation of the TRIF-dependent signaling pathway. Mata-Haro and colleagues (28) reported that MPLA is a weak inducer of MyD88-dependent cytokine production compared with LPS but is equipotent with LPS as an inducer of TRIF-biased cytokines and T-cell clonal expansion. They further demonstrated that TLR4-mediated T-cell activation and clonal expansion are attenuated in mice lacking TRIF- but not MyD88-dependent signaling. In further studies, Gandhapudi et al. (85) confirmed the importance of TRIF-dependent signaling for TLR4 agonist-induced APC maturation as well as T-cell clonal expansion and survival. They showed that type I IFN is the central TRIF-associated gene product driving TLR4-facilitated immunoadjuvant effects including APC maturation and T-cell proliferation and survival, which is consistent with reports by other investigators showing the importance of type I IFN for augmentation of antigen presentation and immunoadjuvant activity (86). Thus, current reports indicate that TRIF-biased signaling is important for facilitating the immunoadjuvant effects of TLR4 agonists. However, further research is needed to fully define the immunological mechanisms involved. Nevertheless, investigators in industry and academia are actively pursuing the development of TLR4 agonists that preferentially induce TRIF-dependent signaling.
AUGMENTATION OF INNATE ANTIMICROBIAL IMMUNITY BY TLR4 AGONISTS
Although TLR4 agonists have gained acceptance as vaccine adjuvants, less attention has been paid to their effectiveness as agents to augment innate antimicrobial responses. Lipopolysaccharide has long been recognized as an agent with potent immunomodulatory properties. However, its significant toxicity has precluded its use as an immunomodulator in humans. In addition, systemic administration of LPS causes development of endotoxin tolerance, and there is a persistent impression that the endotoxin-tolerant phenotype represents a state of immunosuppression. That impression is based on the observation that proinflammatory cytokine production in response to secondary inflammatory stimuli is suppressed in animals that received prior LPS exposure, a characteristic that is also common in conditions that are known to render the host more susceptible to infection such as sepsis, trauma, or major burns (87–89). Legitimate concerns have been raised as to whether suppression of inflammatory responses during endotoxin tolerance would interfere with normal antimicrobial immune responses and thus predispose patients to nosocomial infection. Intact cytokine responses have proven to be necessary for elimination of microbial pathogens during infection of naive animals with small numbers of replicating pathogen. Furthermore, mice deficient in proinflammatory cytokines such as IFN-γ and TNF-α are resistant to inflammatory injury but are highly susceptible to otherwise sublethal bacterial infections (90–92). In addition, endotoxin tolerance leads to an increase in the production of the anti-inflammatory cytokine IL-10 in response to secondary infectious challenge. The effects of IL-10 include inhibition of TH1 cytokine production and attenuation of class II major histocompatibility complex and costimulatory molecule expression on macrophages (93, 94). Elevated IL-10 levels are also characteristic following severe trauma and may contribute to postinjury immunoparalysis (69). Exogenous administration of IL-10 leads to suppression of endotoxin-induced IFN-γ and IL-12 production in the same way, leading to suppression of immune responses and increased susceptibility to infection (95). Thus, the role of IL-10 in perpetuating susceptibility to infection is well documented (96–98). However, Varma et al. (99) demonstrated that whereas endotoxin-tolerant mice exhibit depressed IFN-γ and IL-12 and elevated IL-10 production in response to infection, LPS-primed mice were able to clear a Pseudomonas aeruginosa infection more effectively than nontolerant mice. Depletion of IL-10 in endotoxin-tolerant mice further augmented bacterial clearance, suggesting IL-10 does have a negative impact on the clearance of bacteria, but not enough to negate the beneficial effects of endotoxin priming on bacterial clearance.
Although a small number of studies reported increased susceptibility to infection after prior LPS exposure (100), an emerging body of literature demonstrates that systemic treatment with low to moderate doses of LPS will augment innate antimicrobial responses in a variety of infection models. Deng et al. (101) demonstrate that higher levels of LPS in mice, whether through exogenous administration or through impaired LPS clearance, lead to enhanced macrophage-mediated clearance of bacteria in a model of polymicrobial sepsis. Mice treated with LPS show a drastic reduction in bacterial burden after challenge with either P. aeruginosa or Salmonella enterica serovar typhimurium, despite markedly reduced serum and lung IFN-γ, TNF-α, IL-6, and IL-12 concentrations (102, 103). Because bacterial clearance was enhanced in the face of decreased IFN-γ and IL-12 production, this suggests that these proinflammatory cytokines are not necessary for a competent innate immune response to infection in mice receiving prophylactic treatment with LPS. However, the reduced cytokine production observed in infected LPS-primed mice may also be due to improved bacterial clearance and reduced systemic inflammation due to a decreased bacterial burden. Further studies are needed to define the mechanisms by LPS priming improving bacterial clearance in the face of reduced systemic cytokine production.
Pretreatment with LPS also elicits protection against infection with organisms other than gram-negative bacteria. In a mouse model of Cryptococcus neoformans fungal infection, LPS pretreatment (2.5 μg) for 2 days resulted in decreased fungal burden and improved survival but lower levels of IL-1β, TNF-α, IFN-γ, and IL-6 in the spleen, blood, and lungs in response to fungal infection (104). In addition, LPS pretreatment facilitated enhanced bacterial clearance and improved survival in a model of mouse Staphylococcus aureus infection (105). In further studies, Wheeler et al. (106) demonstrated improved survival and enhanced bacterial clearance following LPS pretreatment in a model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). Thus, it appears that endotoxin-induced augmentation of innate antimicrobial immune responses is not limited to LPS-containing gram-negative organisms but extends to a variety of bacterial and fungal infection models. Furthermore, LPS from E. coli, Pseudomonas, and Salmonella is equally effective at improving bacterial clearance and decreasing mortality after challenge with a variety of organisms (99, 102, 103, 105). Thus, the origin of the LPS used for priming is irrelevant to its function, and LPS appears to induce nonspecific enhancement of innate antimicrobial immunity against a wide spectrum of pathogens.
Monophosphoryl lipid A
As mentioned previously in this review, the heightened toxicity of LPS in humans has precluded its use as an immunomodulator in clinical studies. The identification of less toxic derivatives of LPS has allowed for more clinically relevant investigations of TLR4 agonists. Numerous reports indicate that a variety of TLR4 agonists possess the ability to endotoxin tolerance and enhance host responses to microbial pathogens. Monophosphoryl lipid A preferentially induces TLR4 signaling through the TRIF-dependent signaling pathway, resulting in the stimulation of beneficial immune responses without the excessive production of proinflammatory cytokines (28). Monophosphoryl lipid A can be infused into humans at 5 μg/kg without significant toxicity, a dose that is at least 1,000-fold higher than the tolerable dose of native lipid A (31). Monophosphoryl lipid A will also augment innate host resistance to infection in experimental models. Roquilly et al. (107) reported that treatment of mice exposed to nonlethal hemorrhagic shock protects from developing postinjury pneumonia. Other investigators have reported enhanced host resistance to infection with Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Staphylococcus epidermidis after MPLA treatment (108, 109). Romero et al. (110) reported the protection of mice from clinically relevant models of systemic bacterial infection following prophylactic treatment with MPLA. Both intravenous and intraperitoneal pretreatment with MPLA improved survival, enhanced bacterial clearance, and attenuated proinflammatory cytokine production during polymicrobial infection induced by CLP. In further studies, that group showed that treatment of burned mice with MPLA enhanced their resistance to Pseudomonas burn wound infection. This protection was mediated, in part, by enhanced recruitment of myeloid cells to the site of infection, most notably neutrophils.
In addition to MPLA, a family of synthetic lipid A mimetics termed AGPs can also facilitate innate resistance to infectious challenge. Prophylactic treatment of mice with AGPs has been shown to improve survival following lethal challenge with Listeria monocytogenes or influenza virus. Protection was mediated by a reduction in systemic viral or bacterial load in inoculated animals and was found to be TLR4-dependent (111). Another study found the prophylactic treatment of mice with AGPs led to protection from Yersinia pestis infection, an effect that was also found to be dependent on TLR4 signaling, as TLR4-deficient mice were not protected by MPLA treatment. Protection was associated with a reduction of bacterial load in lung tissue and an enhanced mobilization of neutrophils to the lung (112). In further studies, AGP treatment was shown to decrease bacterial burden and improve survival in an experimental model of pneumonic tularemia (113).
The prospect of developing prophylactic therapies that enhance innate microbial immunity while controlling excessive inflammation may be particularly beneficial for at-risk or immune-compromised individuals who are at increased risk of developing severe secondary and nosocomial infections. This approach has significant clinical relevance, as TLR4 agonists could be administered to patients before undergoing high-risk surgical procedures to lessen the incidence or severity of postoperative infection and inflammation-induced morbidity. Patients who have suffered major trauma or burns or who have survived the acute phase of sepsis are also at increased risk of developing nosocomial infections and might benefit from immunoprophylaxis facilitated by administration of lipid A mimetics.
CELLULAR MECHANISMS BY WHICH TLR4 AGONISTS ENHANCE INNATE ANTIMICROBIAL RESPONSES
The mechanisms by which pretreatment with TLR4 agonists leads to enhanced clearance of infection to subsequent pathogen exposure remain to be fully elucidated. Several studies have focused on the enhancement of innate effector cell responses induced by prior exposure to TLR4 agonists. Enhancements in the recruitment and phagocytic functions of macrophages and neutrophils have been observed. Improved recruitment, expansion, and/or functional modifications of these innate effector cells responsible for pathogen clearance could explain enhanced clearance of infection.
Wheeler and colleagues (106) demonstrated that LPS pretreatment improved bacterial clearance and survival in a model of CLP-induced sepsis. They further showed that LPS treatment increased phagocytosis by macrophages after in vivo infection with fluorochrome-tagged E. coli or S. aureus (106). These findings confirmed earlier reports that showed preconditioning macrophages and mononuclear cells with small doses of LPS resulted in both decreased proinflammatory cytokine production in response to a subsequent dose of LPS in vitro or in vivo and increased bacterial phagocytosis (114). Other studies have demonstrated a potential role of hepatic macrophages (Kupffer cells) in LPS-augmented bacterial clearance (103, 115, 116).
Increased recruitment of innate effector cells to the site of infection may also underlie enhanced bacterial clearance in mice receiving prophylactic treatment with TLR4 agonists. Some studies have shown that both LPS and MPLA facilitate local recruitment of neutrophils to sites of infection but do not change the phagocytic activity of macrophages and neutrophils on a per cell basis (104, 106, 110, 117). The accumulation of neutrophils at the site of infection appears to be critical for augmented bacterial clearance because neutrophil depletion ablated the beneficial antimicrobial effects of lipid A mimetics. Yet, the mechanisms by which TLR4 agonists facilitate myeloid cell recruitment to sites of infection remain to be determined. However, several potential mechanisms warrant investigation (Table 2). Perhaps TLR4 agonist pretreatment is able to enhance the directionality and/or responsiveness of myeloid cells in response to pathogen detection, allowing effector cells to be more rapidly and efficiently recruited to site of infection, where they can clear the pathogen. Those changes could be mediated by increased expression of chemokines and/or chemoattractant receptors by leukocytes from subjects treated with lipid A mimetics. Lipid A mimetics may also increase expression of adhesion molecules on leukocytes and/or endothelial cells, resulting in improved leukocyte binding and chemotaxis. As noted earlier, the ability of lipid A mimetics to improve the phagocytic and killing functions of neutrophils is somewhat controversial and requires further investigation.
Lipid A is a potent activator of innate immune responses. Activation of the LPS receptor complex by native lipid A induces robust cytokine production, leukocyte activation, and inflammation, which provides attractive immunological characteristics but is associated with the pronounced inflammatory responses and limits its use as a clinical immunomodulator. Analogs of lipid A have been generated that possess greatly attenuated proinflammatory activity but retain attractive properties as immunoadjuvants. For example, the lipid A analog MPLA exhibits approximately 1/1,000th of the toxicity of native lipid A but retains potent immunoadjuvant activity and is currently used as an adjuvant in several human vaccine preparations. Because of the potency of lipid A analogs as immunoadjuvants, numerous laboratories are actively working to identify and develop new lipid A mimetics and to optimize their efficacy and safety. In addition to their value as vaccine immunoadjuvants, lipid A analogs potently facilitate innate immune responses to bacterial, viral, and fungal infections when given prophylactically. Treatment with lipid A mimetics augments the recruitment of myeloid cells, particularly neutrophils, to sites of infection and may enhance neutrophil phagocytic and killing functions. Based on those characteristics, lipid A analogs represent an attractive family of immunomodulators that could have clinical application in patients at risk for developing opportunistic and/or nosocomial infections.
1. Schweizer HP: Understanding efflux in gram-negative bacteria: opportunities for drug discovery. Expert Opin Drug Discov 7 (7): 633–642, 2012.
2. Schmidt H, Hansen G, Singh S, Hanuszkiewicz A, Lindner B, Fukase K, Woodard RW, Holst O, Hilgenfeld R, Mamat U, et al.: Structural and mechanistic analysis of the membrane-embedded glycosyltransferase WaaA required for lipopolysaccharide synthesis. Proc Natl Acad Sci U S A. 2012; 109 (16): 6253–8. Epub 2012/04/05. doi: 10.1073/pnas.1119894109. PubMed PMID: 22474366; PubMed Central PMCID: PMC3341020.
3. Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA: Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 33 (3): 798–805, 2003.
4. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO: The structural basis of lipopolysaccharide recognition by the TLR4
-MD-2 complex. Nature 458 (7242): 1191–1195, 2009.
5. Asai Y, Hashimoto M, Fletcher HM, Miyake K, Akira S, Ogawa T: Lipopolysaccharide preparation extracted from Porphyromonas gingivalis
lipoprotein-deficient mutant shows a marked decrease in Toll-like receptor 2-mediated signaling. Infect Immun 73 (4): 2157–2163, 2005.
6. Namas R, Zamora R, An G, Doyle J, Dick TE, Jacono FJ, Androulakis IP, Nieman GF, Chang S, et al.: Something old, something new, and a systems view. J Crit Care. 2012; 27 (3): 314 e1–11. Epub 2011/07/30. doi: 10.1016/j.jcrc.2011.05.025. PubMed PMID: 21798705; PubMed Central PMCID: PMC3206132.
7. Vandenbon A, Teraguchi S, Akira S, Takeda K, Standley DM: Systems biology approaches to Toll-like receptor signaling. Wiley Interdiscip Rev Syst Biol Med 4 (5): 497–507, 2012.
8. Dauphinee SM, Karsan A: Lipopolysaccharide signaling in endothelial cells. Lab Invest 86 (1): 9–22, 2006.
9. Carpenter S, O’Neill LA: Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 422 (1): 1–10, 2009.
10. Ebong SJ, Goyert SM, Nemzek JA, Kim J, Bolgos GL, Remick DG: Critical role of CD14 for production of proinflammatory cytokines and cytokine inhibitors during sepsis with failure to alter morbidity or mortality. Infect Immun 69 (4): 2099–2106, 2001.
11. Casella CR, Mitchell TC: Putting endotoxin
to work for us: monophosphoryl lipid A
as a safe and effective vaccine adjuvant
. Cell Mol Life Sci 65 (20): 3231–3240, 2008.
12. Kawai T, Akira S: Toll-like receptor downstream signaling. Arthritis Res Ther 7 (1): 12–19, 2005.
13. Akira S: TLR signaling. Curr Top Microbiol Immunol 311: 1–16, 2006.
14. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr., MyD88
is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998; 2 (2): 253–258. Epub 1998/09/12. PubMed PMID: 9734363.
15. Li X, Commane M, Jiang Z, Stark GR: IL-1–induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor–associated kinase (IRAK). Proc Natl Acad Sci U S A 98 (8): 4461–4465, 2001.
16. Akira S, Sato S: Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 35 (9): 555–562, 2003.
17. Aksoy E, Taboubi S, Torres D, Delbauve S, Hachani A, Whitehead MA, Pearce WP, Berenjeno IM, Nock G, Filoux A, et al.: The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4
signaling and protects from endotoxic shock. Nat Immunol. 2012; 13 (11): 1045–1054. Epub 2012/10/02. doi: 10.1038/ni.2426. PubMed PMID: 23023391.
18. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R: TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 9 (4): 361–368, 2008.
19. Jiang Z, Mak TW, Sen G, Li X: Toll-like receptor 3–mediated activation of NF-kappaB and IRF3 diverges at Toll–IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A 101 (10): 3533–3538, 2004.
20. Husebye H, Halaas O, Stenmark H, Tunheim G, Sandanger O, Bogen B, Brech A, Latz E, Espevik T Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J. 2006 25 (4): 683–692. Epub 2006/02/10. doi: 10.1038/sj.emboj.7600991. PubMed PMID: 16467847; PubMed Central PMCID: PMC1383569.
21. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, et al.: Role of adaptor TRIF
in the MyD88
-independent Toll-like receptor signaling pathway. Science. 2003; 301 (5633): 640–643. Epub 2003/07/12. doi: 10.1126/science.1087262. PubMed PMID: 12855817.
22. Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS: Modulating the innate immune response by combinatorial engineering of endotoxin
. Proc Natl Acad Sci U S A 110 (4): 1464–1469, 2013.
23. Raetz CR, Guan Z, Ingram BO, Six DA, Song F, Wang X, Zhao J. Discovery of new biosynthetic pathways: the lipid A
story. J Lipid Res. 2009; (Suppl 50): S103–S108. Epub 2008/11/01. doi: 10.1194/jlr.R800060-JLR200. PubMed PMID: 18974037; PubMed Central PMCID: PMC2674688.
24. Akira S: Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 28 (5): 551–556, 2000.
25. Bolz DD, Sundsbak RS, Ma Y, Akira S, Weis JH, Schwan TG, Weis JJ Dual role of MyD88
in rapid clearance of relapsing fever Borrelia
spp. Infect Immun. 2006; 74 (12): 6750–6760. Epub 2006/10/13. doi: 10.1128/IAI.01160-06. PubMed PMID: 17030581; PubMed Central PMCID: PMC1698049.
26. Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, Burns K, Riederer BM, Akira S, Calandra T Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A. 2009; 106 (7): 2348–2352. Epub 2009/02/03. doi: 10.1073/pnas.0808146106. PubMed PMID: 19181857; PubMed Central PMCID: PMC2650125.
27. Takeda K, Akira S: TLR signaling pathways. Semin Immunol 16 (1): 3–9, 2004.
28. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC: The vaccine adjuvant
monophosphoryl lipid A
as a TRIF
-biased agonist of TLR4
. Science 316 (5831): 1628–1632, 2007.
29. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC: Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A
. J Biol Chem 84 (46): 31982–31991, 2009.
30. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA: Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 12 (6): 648–657, 2012.
31. Astiz ME, Rackow EC, Still JG, Howell ST, Cato A, Von Eschen KB, Ulrich JT, Redbach JA, McMahon G, Vargas R, et al.: Pretreatment of normal humans with monophosphoryl lipid A
induces tolerance to endotoxin
: a prospective, double-blind, randomized, controlled trial. Crit Care Med. 1995; 23 (1): 9–17. Epub 1995/01/01. PubMed PMID: 8001393.
32. Astiz ME, Rackow EC, Kim YB, Weil MH: Monophosphoryl lipid A
induces tolerance to the lethal hemodynamic effects of endotoxemia. Circ Shock 33 (2): 92–97, 1991.
33. Casella CR, Mitchell TC: Inefficient TLR4
/MD-2 heterotetramerization by monophosphoryl lipid A
. PLoS One 8 (4): e62622, 2013.
34. Alving CR, Peachman KK, Rao M, Reed SG: Adjuvants for human vaccines. Curr Opin Immunol 24 (3): 310–315, 2012.
35. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT: Selective TRIF
-dependent signaling by a synthetic Toll-like receptor 4 agonist. Sci Signal 5 (211): ra13, 2012.
36. Xiong Y, Medvedev AE: Induction of endotoxin
tolerance in vivo
inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol 90 (6): 1141–1148, 2011.
37. Varma TK, Toliver-Kinsky TE, Lin CY, Koutrouvelis AP, Nichols JE, Sherwood ER: Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin
-tolerant mice. Infect Immun 69 (9): 5249–5263, 2001.
38. Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN: Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A
prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect Immun 66 (8): 3569–3578, 1998.
39. Biswas SK, Lopez-Collazo E: Endotoxin
tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30 (10): 475–487, 2009.
40. Flohe S, Lendemans S, Schade FU, Kreuzfelder E, Waydhas C: Influence of surgical intervention in the immune response of severely injured patients. Intensive Care Med 30 (1): 96–102, 2004.
41. Cavaillon JM, Adib-Conquy M: Bench-to-bedside review: endotoxin
tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 10 (5): 233, 2006.
42. Gahring LC, Daynes RA: Desensitization of animals to the inflammatory effects of ultraviolet radiation is mediated through mechanisms which are distinct from those responsible for endotoxin
tolerance. J Immunol 136 (8): 2868–2874, 1986.
43. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, et al.: Intravenous endotoxin
suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151 (3): 1637–1645, 1993.
44. Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN, et al.: Induction of in vitro
reprogramming by Toll-like receptor (TLR)2 and TLR4
agonists in murine macrophages: effects of TLR “homotolerance” versus “heterotolerance” on NF-kappa B signaling pathway components. J Immunol. 2003; 170 (1): 508–519. Epub 2002/12/24. PubMed PMID: 12496438.
45. Jacinto R, Hartung T, McCall C, Li L: Lipopolysaccharide- and lipoteichoic acid–induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor–associated kinase. J Immunol 168 (12): 6136–6141, 2002.
46. Li CH, Wang JH, Redmond HP: Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88
-IRAK complex formation. J Leukoc Biol 79 (4): 867–875, 2006.
47. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ: Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 165 (2): 618–622, 2000.
48. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J MyD88
-dependent and MyD88
-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol. 2007; 178 (2): 1164–1171. Epub 2007/01/05. PubMed PMID: 17202381.
49. Sato S, Takeuchi O, Fujita T, Tomizawa H, Takeda K, Akira S: A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88
-dependent and -independent pathways. Int Immunol 14 (7): 783–791, 2002.
50. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 13 (2): 85–94, 2001.
51. Medvedev AE, Sabroe I, Hasday JD, Vogel SN: Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin
Res 12 (3): 133–150, 2006.
52. Piao W, Song C, Chen H, Diaz MA, Wahl LM, Fitzgerald KA, Li L, Medvedev AE Endotoxin
tolerance dysregulates MyD88
- and Toll/IL-1R domain-containing adapter inducing IFN-beta–dependent pathways and increases expression of negative regulators of TLR signaling. J Leukoc Biol. 2009; 86 (4): 863–875. Epub 2009/08/07. doi: 10.1189/jlb.0309189. PubMed PMID: 19656901; PubMed Central PMCID: PMC2796624.
53. Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1 (6): a001651, 2009.
54. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110 (2): 191–202, 2002.
55. Lawrence T, Fong C: The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 42 (4): 519–523, 2010.
56. Chen X, El Gazzar M, Yoza BK, McCall CE: The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin
tolerance. J Biol Chem 284 (41): 27857–27865, 2009.
57. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA: Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7 (12): 1291–1297, 2001.
58. Su J, Xie Q, Wilson I, Li L: Differential regulation and role of interleukin-1 receptor associated kinase-M in innate immunity
signaling. Cell Signal 19 (7): 1596–1601, 2007.
59. Deng H, Maitra U, Morris M, Li L: Molecular mechanism responsible for the priming of macrophage activation. J Biol Chem 288 (6): 3897–3906, 2013.
60. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447 (7147): 972–978, 2007.
61. El Gazzar M, McCall CE: MicroRNAs distinguish translational from transcriptional silencing during endotoxin
tolerance. J Biol Chem 285 (27): 20940–20951, 2010.
62. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB–dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103 (33): 12481–12486, 2006.
63. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, et al.: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin
shock. J Immunol 179 (8): 5082–5089, 2007.
64. El Gazzar M, Yoza BK, Chen X, Garcia BA, Young NL, McCall CE: Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin
tolerance. Mol Cell Biol 29 (7): 1959–1971, 2009.
65. El Gazzar M, Yoza BK, Chen X, Hu J, Hawkins GA, McCall CE: G9a and HP1 couple histone and DNA methylation to TNFalpha transcription silencing during endotoxin
tolerance. J Biol Chem 283 (47): 32198–32208, 2008.
66. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, et al.: SOCS-1 participates in negative regulation of LPS responses. Immunity. 2002; 17 (5): 677–687. Epub 2002/11/16. PubMed PMID: 12433373.
67. Liu ZJ, Liu XL, Zhao J, Shi YJ, Yan LN, Chen XF, Li XH, You HB, Xu FL, Gong JP, et al.: The effects of SOCS-1 on liver endotoxin
tolerance development induced by a low dose of lipopolysaccharide are related to dampen NF-kappaB–mediated pathway. Dig Liver Dis. 2008; 40 (7): 568–577. Epub 2008/04/02. doi: 10.1016/j.dld.2007.12.019. PubMed PMID: 18378198.
68. Adib-Conquy M, Adrie C, Moine P, Asehnoune K, Fitting C, Pinsky MR, Dhainaut JF, Cavaillon JM NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med. 2000; 162 (5): 1877–1883. Epub 2000/11/09. PubMed PMID: 11069829.
69. Wolk K, Docke W, von Baehr V, Volk H, Sabat R: Comparison of monocyte functions after LPS- or IL-10–induced reorientation: importance in clinical immunoparalysis. Pathobiology 67 (5–6): 253–256, 1999.
70. Kwissa M, Nakaya HI, Oluoch H, Pulendran B: Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119 (9): 2044–2055, 2012.
71. Alving CR: Lipopolysaccharide, lipid A
, and liposomes containing lipid A
as immunologic adjuvants. Immunobiology 187 (3–5): 430–446, 1993.
72. Kaisho T, Akira S: Toll-like receptors as adjuvant
receptors. Biochim Biophys Acta 1589 (1): 1–13, 2002.
73. Kaisho T, Akira S: Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 3 (4): 373–385, 2003.
74. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal–regulated kinase–mitogen-activated protein kinase and c-Fos. J Immunol. 2003; 171 (10): 4984–9. Epub 2003/11/11. PubMed PMID: 14607893.
75. Pantel A, Cheong C, Dandamudi D, Shrestha E, Mehandru S, Brane L, Ruane D, Teixeira A, Bozzacco L, Steinman RM, et al.: A new synthetic TLR4
agonist, GLA, allows dendritic cells targeted with antigen to elicit TH
1 T-cell immunity in vivo
. Eur J Immunol. 2012; 42 (1): 101–9. Epub 2011/10/18. doi: 10.1002/eji.201141855. PubMed PMID: 22002164; PubMed Central PMCID: PMC3517108.
76. Watanabe S, Inoue J: Intracellular delivery of lipopolysaccharide induces effective TH
1-immune responses independent of IL-12. PLoS One 8 (7): e68671, 2013.
77. McAleer JP, Vella AT: Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit Rev Immunol 28 (4): 281–299, 2008.
78. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Persing D Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004; 4 (7): 1129–38. Epub 2004/07/23. doi: 10.1517/14712522.214.171.1249. PubMed PMID: 15268679.
79. Kundi M: New hepatitis B vaccine formulated with an improved adjuvant
system. Expert Rev Vaccines 6 (2): 133–140, 2007.
80. Garcon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M: Development of an AS04-adjuvanted HPV vaccine with the adjuvant
system approach. BioDrugs 25 (4): 217–226, 2011.
81. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G, et al.: Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. 2009; Hum Vaccine 5 (5): 332–40. Epub 2009/02/18. PubMed PMID: 19221517.
82. Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, et al.: Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-seronegative African girls and young women. J Infect Dis. 2013; 207 (11): 1753–63. Epub 2012/12/18. doi: 10.1093/infdis/jis619. PubMed PMID: 23242542; PubMed Central PMCID: PMC3636781.
83. Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA, Szuts P, O’Mahony M, David MP, Dobbelaere K, et al.: Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health. 2012; 50 (1): 38–46. Epub 2011/12/23. doi: 10.1016/j.jadohealth.2011.10.009. PubMed PMID: 22188832.
84. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG Taking Toll: lipid A
mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002; 10 (Suppl 10): S32–S7. Epub 2002/10/16. PubMed PMID: 12377566.
85. Gandhapudi SK, Chilton PM, Mitchell TC: TRIF
is required for TLR4
effects on T cell clonal expansion. PLoS One 8 (2): e56855, 2013.
86. Oh JZ, Kurche JS, Burchill MA, Kedl RM: TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118 (11): 3028–3038, 2011.
87. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER: Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 21 (5): 415–425, 2004.
88. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012; 72 (6): 1491–501. Epub 2012/06/15. doi: 10.1097/TA.0b013e318256e000. PubMed PMID: 22695412.
89. Wysocka M, Montaner LJ, Karp CL: Flt3 ligand treatment reverses endotoxin
tolerance-related immunoparalysis. J Immunol 174 (11): 7398–7402, 2005.
90. Dai WJ, Bartens W, Kohler G, Hufnagel M, Kopf M, Brombacher F: Impaired macrophage listericidal and cytokine activities are responsible for the rapid death of Listeria monocytogenes
–infected IFN-gamma receptor–deficient mice. J Immunol 158 (11): 5297–5304, 1997.
91. O’Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH: Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae
infections. Infect Immun 67 (2): 595–601, 1999.
92. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkemagel R, Steinmetz M, Bluethmann H Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
. Nature. 1993; 364 (6440): 798–802. Epub 1993/08/26. doi: 10.1038/364798a0. PubMed PMID: 8395024.
93. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 22: 929–979, 2004.
94. Rossato M, Curtale G, Tamassia N, Castellucci M, Mori L, Gasperini S, Mariotti B, De Luca M, Mirolo M, Cassatella MA, et al.: IL-10–induced microRNA-187 negatively regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4
-stimulated monocytes. Proc Natl Acad Sci U S A. 2012; 109 (45): E3101–E310. Epub 2012/10/17. doi: 10.1073/pnas.1209100109. PubMed PMID: 23071313; PubMed Central PMCID: PMC3494907.
95. Grutz G: New insights into the molecular mechanism of interleukin-10–mediated immunosuppression. J Leukoc Biol 77 (1): 3–15, 2005.
96. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der Poll T IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004; 172 (12): 7603–9. Epub 2004/06/10. PubMed PMID: 15187140.
97. Metzger DW, Salmon SL, Kirimanjeswara G: Differing Effects of IL-10 in Cutaneous and Pulmonary Francisella tularensis
LVS Infection. Infect Immun. 2013; 81 (6): 2022–7. Epub 2013/03/27. doi: 10.1128/IAI.00024-13. PubMed PMID: 23529615.
98. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP: IL-10 mediates susceptibility to Leishmania donovani
infection. Eur J Immunol 31 (10): 2848–2856, 2001.
99. Varma TK, Durham M, Murphey ED, Cui W, Huang Z, Lin CY, Toliver-Kinsky T, Sherwood ER Endotoxin
priming improves clearance of Pseudomonas aeruginosa
in wild-type and interleukin-10 knockout mice. Infect Immun. 2005; 73 (11): 7340–7347. Epub 2005/10/22. doi: 10.1128/IAI.73.11.7340–7347.2005. PubMed PMID: 16239532; PubMed Central PMCID: PMC1273831.
100. Mason CM, Dobard E, Summer WR, Nelson S: Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms. J Infect Dis 176 (5): 1293–1302, 1997.
101. Deng M, Scott MJ, Loughran P, Gibson G, Sodhi C, Watkins S, Hackam D, Billiar TR Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4
during sepsis. J Immunol. 2013; 190 (10): 5152–60. Epub 2013/04/09. doi: 10.4049/jimmunol.1300496. PubMed PMID: 23562812; PubMed Central PMCID: PMC3644895.
102. Murphey ED, Fang G, Varma TK, Sherwood ER: Improved bacterial clearance and decreased mortality can be induced by LPS tolerance and is not dependent upon IFN-gamma. Shock 27 (3): 289–295, 2007.
103. Lehner MD, Ittner J, Bundschuh DS, van Rooijen N, Wendel A, Hartung T: Improved innate immunity
-tolerant mice increases resistance to Salmonella enterica
infection despite attenuated cytokine response. Infect Immun 69 (1): 463–471, 2001.
104. Rayhane N, Fitting C, Lortholary O, Dromer F, Cavaillon JM: Administration of endotoxin
associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun 68 (6): 3748–3753, 2000.
105. Murphey ED, Fang G, Sherwood ER: Endotoxin
pretreatment improves bacterial clearance and decreases mortality in mice challenged with Staphylococcus aureus
. Shock 29 (4): 512–518, 2008.
106. Wheeler DS, Lahni PM, Denenberg AG, Poynter SE, Wong HR, Cook JA, Zingarelli B Induction of endotoxin
tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock. 2008; 30 (3): 267–73. Epub 2008/01/17. doi: 10.1097/shk.0b013e318162c190. PubMed PMID: 18197145; PubMed Central PMCID: PMC2754132.
107. Roquilly A, Broquet A, Jacqueline C, Gautreau L, Segain JP, de Coppet P, Caillon J, Altare F, Josien R, Asehnoune K, et al.: TLR-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur Respir J 2013. Epub 2013/01/15. doi: 10.1183/09031936.00152612. PubMed PMID: 23314895.
108. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M: Monophosphoryl lipid A
induced innate immune responses via TLR4
to enhance clearance of nontypeable Haemophilus influenzae
and Moraxella catarrhalis
from the nasopharynx in mice. FEMS Immunol Med Microbiol 63 (3): 407–417, 2011.
109. Chase JJ, Kubey W, Dulek MH, Holmes CJ, Salit MG, Pearson FC 3rd, Ribi E Effect of monophosphoryl lipid A
on host resistance to bacterial infection. Infect Immun. 1986; 53 (3): 711–2. Epub 1986/09/01. PubMed PMID: 3744562; PubMed Central PMCID: PMC260854.
110. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER: The Toll-like receptor 4 agonist monophosphoryl lipid A
augments innate host resistance to systemic bacterial infection. Infect Immun 79 (9): 3576–3587, 2011.
111. Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, Brookshire VG, Wang R, Ward JR, Yorgensen YM, Persing DH, et al.: Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J Endotoxin
Res. 2002; 8 (6): 453–8. Epub 2003/04/17. doi: 10.1179/096805102125001064. PubMed PMID: 12697089.
112. Airhart CL, Rohde HN, Bohach GA, Hovde CJ, Deobald CF, Lee SS, Minnich SA. Induction of innate immunity
by lipid A
mimetics increases survival from pneumonic plague. Microbiology. 2008; 154 (Pt 7): 2131–8. Epub 2008/07/05. doi: 10.1099/mic.0.2008/017566-0. PubMed PMID: 18599840.
113. Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC, West TE, Wilson CB, Haijar AM, Skerrett SJ. Administration of a synthetic TLR4
agonist protects mice from pneumonic tularemia. J Immunol. 2008; 180 (11): 7574–81. Epub 2008/05/21. PubMed PMID: 18490759; PubMed Central PMCID: PMC3063511.
114. Lehner MD, Hartung T: Endotoxin
tolerance-mechanisms and beneficial effects in bacterial infection. Rev Physiol Biochem Pharmacol 144: 95–141, 2002.
115. Hafenrichter DG, Roland CR, Mangino MJ, Flye MW: The Kupffer cell in endotoxin
tolerance: mechanisms of protection against lethal endotoxemia. Shock 2 (4): 251–256, 1994.
116. Ruggiero G, Andreana A, Utili R, Galante D: Enhanced phagocytosis and bactericidal activity of hepatic reticuloendothelial system during endotoxin
tolerance. Infect Immun 27 (3): 798–803, 1980.
117. Astiz ME, Saha DC, Carpati CM, Rackow EC: Induction of endotoxin
tolerance with monophosphoryl lipid A
in peritonitis: importance of localized therapy. J Lab Clin Med 123 (1): 89–93, 1994.